ACTRN12623000149662Not yet recruiting未知
An observational study investigating the safety, tolerability and health outcomes of cannabinoid therapy prescribed to eligible patients for management of recognized chronic conditions
Cloud Medical PTY LTD0 sites2,000 target enrollmentStarted: February 15, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 2,000
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to 101 Years (—)
- Sex
- All
Inclusion Criteria
- •1. Prospective participants must be greater than to equal to 18 years of age at time of entry on study
- •2. Prospective participants must be willing and able to understand the informed consent process, provide informed consent, and participate in the observational study
- •3. Prospective participants must be eligible to be lawfully prescribed cannabinoid therapy by their Physician
- •4. Prospective participants agree to abstain from using cannabinoid therapy other than the therapy that is prescribed by their Physician
Exclusion Criteria
- •1. Prospective participants are ineligible if they are under the age of 18
- •2. Prospective participants are ineligible if they are unwilling, unable or cannot understand the informed consent form
- •3. Prospective participants are ineligible if their Physician determines that the prospective participant is unable to fulfill any requirements of the study
- •4. Prospective participants are ineligible if they are currently using illicit drugs and/or with alcohol abuse.
- •5. Prospective patients are ineligible if any of the following are met:
- •5.1. Have an active or previous psychotic or active mood or anxiety disorder
- •5.2. Women who are pregnant, planning to become pregnant or breastfeeding
- •5.3. Have unstable cardiovascular disease
Investigators
Similar Trials
Recruiting
Not Applicable
An observational study to evaluate the safety and efficacy of MegaDerm Soft in patients who underwent breast reconstruction using the MegaDerm soft.KCT0007432Soon Chun Hyang University Hospital Bucheon60
Recruiting
Phase 4
An observational study to evaluate the safety and efficacy of FOLFIRI / FOLFOX plus Cetuximab as first-line therapy inpatients with KRAS wild-type metastatic Colorectal cancerCTRI/2010/091/000161Merck Specialities Pvt Limited5th Floor , Shivsagar EstateDr. Annie Besant RoadMumbai 400018100
Not yet recruiting
Unknown
An observational study to evaluate the safety and efficacy of lenvatinib plus pembrolizumab combination therapy for advanced or recurrent uterine cancer after use of platinum-based drugs(GOGO-EM4)JPRN-UMIN000049997Gynecologic Oncology Group of Osaka(GOGO)100
Recruiting
Phase 4
An Observational Study to evaluate the safety and efficacy of Cetuximab in combination with platinum-based chemotherapy, in the first-line therapy of recurrent/ metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)CTRI/2010/091/000170Merck Specialities Pvt Ltd5th Floor Shiv Sagar Estate, Dr. Aniie Besant Road, WorliMumbai 400018100
Completed
Not Applicable
A observational study to investigate the safety and efficacy of olaparib combined with bevacizumab therapy after primary chemotherapy plus bevacizumab for Japanese patients with advanced ovarian, fallopian tube, or primary peritoneal cancer.Ovarian cancer, Fallopian tube cancer, Primary peritoneal cancerJPRN-UMIN000047107Japanese Gynecologic Oncology Group300